BBB

Celgene Corporation 3.9% 20-FEB-2028

No trades
See on Supercharts
Overview
Analysis

BMY4597873 analysis



Key facts


Issuer
Celgene Corp.
Issue date
Feb 20, 2018
Maturity date
Feb 20, 2028
Outstanding amount
‪43.84 M‬USD
Face value
1,000.00USD
Minimum denomination
2,000.00USD
Coupon
3.90% (Fixed)
Yield to maturity
5.08%
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.